This website uses cookies to improve the site and user experience. By continuing to browse this site,
you agree to accept our use of cookies. For more information, please review our Cookies Policy
February 2021
Presentations

HEOR | Urothelial Carcinoma | Abstract 414
Treatment patterns among patients with advanced urothelial carcinoma following discontinuation of PD1/L1 inhibitor therapy

Tucatinib | Gastric or GEJ Cancers | TPS252
MOUNTAINEER-02 TIP: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma: Trial in Progress

Ladiratuzumab vedotin | Prostate Cancer | Abstract TPS185
SGNLVA-005 TIP: Open-Label, Phase 2 Study of Ladiratuzumab Vedotin (LV) for Advanced Gastric and Gastroesophageal Junction Adenocarcinoma (SGNLVA-005, Trial in Progress)

Enfortumab vedotin | Urothelial Carcinoma| Abstract 393
Primary results of EV-301: A phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial carcinoma

EV-201 Cohort 2: Enfortumab vedotin in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors
Videos
Enfortumab vedotin | Urothelial Carcinoma| Abstract 393
Primary results of EV-301: A phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial carcinoma
Enfortumab vedotin| Urothelial Carcinoma| Abstract 394
EV-201 Cohort 2: Enfortumab vedotin in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors